{"gene":"CRLF1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2007,"finding":"CRLF1 forms a heterodimer complex with cardiotrophin-like cytokine factor 1 (CLCF1/CLC), and this heterodimer competes with ciliary neurotrophic factor (CNTF) for binding to the CNTF receptor (CNTFR) complex, placing CRLF1 in the CNTFR signaling pathway.","method":"Biochemical characterization; mutation analysis; mRNA expression in patient fibroblasts by real-time quantitative PCR","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — established by two independent groups in the same journal issue (PMID 17436251, 17436252), supported by prior literature on the heterodimer complex and consistent functional framing","pmids":["17436251","17436252"],"is_preprint":false},{"year":2002,"finding":"Loss-of-function mutations in CRLF1 cause cold-induced sweating syndrome (CISS1), an autosomal recessive disorder, indicating that CRLF1 is required for normal developmental and autonomic nervous system function.","method":"Genome-wide linkage mapping, candidate region fine-mapping, DNA sequencing in affected families","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic mapping and sequencing in multiple families, independently replicated in subsequent studies","pmids":["12509788"],"is_preprint":false},{"year":2011,"finding":"Phenotypic severity of CRLF1-associated disorders (Crisponi syndrome vs. CISS1) mainly depends on altered kinetics of secretion of the mutated CRLF1 protein; mutations that more severely impair CRLF1 secretion correlate with more severe clinical outcome.","method":"Functional secretion assays of mutant CRLF1 proteins from patient-derived or transfected cells; clinical analysis of 19 patients","journal":"European journal of human genetics : EJHG","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — secretion kinetics assayed in cells for multiple mutations, correlated with clinical data in a large patient cohort; single lab","pmids":["21326283"],"is_preprint":false},{"year":2013,"finding":"CRLF1 protects differentiated neuroblastoma cells against 6-hydroxydopamine-induced oxidative stress by a cell-autonomous mechanism that is independent of its known role as a co-ligand for the CNTF receptor (gp130/JAK signaling pathway).","method":"Loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in neuroblastoma cells; 6-OHDA toxicity assay; differentiation state comparison","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both necessary and sufficient evidence by KD and OE, receptor-independence tested directly; single lab","pmids":["23818941"],"is_preprint":false},{"year":2017,"finding":"CLF-1 (CRLF1) contains a binding site for the endocytic receptor sorLA; sorLA-expressing cells rapidly internalize CLF-1 and CLC:CLF-1, and in cells co-expressing CNTFRα and sorLA, CLF-1 bridges CNTFRα to sorLA, driving CNTFRα internalization and lysosomal degradation, thereby downregulating surface CNTFRα and reducing CLC:CLF-1 signaling.","method":"Western blotting, lysosomal enzyme inhibition, immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1","journal":"Journal of visualized experiments : JoVE","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Western blot, inhibitor studies, immunocytochemistry), single lab","pmids":["28117780"],"is_preprint":false},{"year":2018,"finding":"CRLF1 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition in papillary thyroid carcinoma cells by activating the ERK1/2 and AKT signaling pathways; these oncogenic effects are suppressed by MEK inhibitor U0126 or AKT inhibitor MK-2206.","method":"Loss-of-function and gain-of-function assays in PTC cell lines; in vitro migration/invasion; in vivo tumor growth; Western blotting of ERK1/2 and AKT phosphorylation; pharmacological inhibition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays (in vitro and in vivo), pathway validated by specific inhibitors; single lab","pmids":["29515111"],"is_preprint":false},{"year":2020,"finding":"CRLF1 directly binds MYH9, which enhances CRLF1 protein stability; this interaction promotes PTC cell proliferation and metastasis via ERK pathway activation and upregulation of transcription factor ETV4, which in turn binds the MMP1 promoter to induce MMP1 expression.","method":"Co-immunoprecipitation (direct binding), RNA-sequencing (ETV4 as downstream target), ChIP assay (ETV4 binding MMP1 promoter), in vitro and in vivo functional assays, Western blotting","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, RNA-seq, in vivo validation; single lab","pmids":["32982961"],"is_preprint":false},{"year":2020,"finding":"TGF-β1 upregulates CRLF1 mRNA expression in ligamentum flavum cells via the SMAD3 pathway; CRLF1 in turn enhances fibrosis via ERK signaling at the post-transcriptional level, and CRLF1 knockdown reduces fibrosis caused by inflammatory cytokines and mechanical stress. In vivo, CRLF1 overexpression causes ligamentum flavum hypertrophy.","method":"Transcriptome and proteomics of human LF tissue; immunohistochemistry; SMAD3 pathway inhibitor studies; CRLF1 knockdown and overexpression in vivo (bipedal-standing mouse model) and in vitro","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including in vivo mouse model and in vitro mechanistic dissection; single lab","pmids":["33072735"],"is_preprint":false},{"year":2021,"finding":"miR-3065-3p directly targets and suppresses CRLF1 mRNA (validated by luciferase reporter assay), and CRLF1 acts downstream of miR-3065-3p to inhibit stemness in colorectal cancer; CRLF1 knockdown promotes, and its overexpression restores, the pro-stemness effects regulated by this miRNA.","method":"Luciferase reporter assay for direct miR-3065-3p/CRLF1 interaction; gain/loss-of-function in colorectal cancer cell lines and orthotopic xenograft; stemness markers (NANOG, OCT4, SOX2, ALDH activity, sphere formation)","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction validated by luciferase assay, functional rescue experiments, in vivo model; single lab","pmids":["34656128"],"is_preprint":false},{"year":2021,"finding":"CRLF1 is a direct target of miR-320 in bone marrow-derived mesenchymal stem cells (BMSCs); suppression of CRLF1 promotes chondrogenic differentiation of BMSCs and protects cartilage from OA damage; miR-320 overexpression reverses CRLF1-driven inhibition of chondrogenesis and promotion of apoptosis.","method":"Luciferase reporter assay; miR-320 overexpression; CRLF1 knockdown; chondrogenic differentiation assays in BMSCs; DMM mouse OA model","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting validated, functional rescue in vitro and in vivo OA model; single lab","pmids":["34551709"],"is_preprint":false},{"year":2023,"finding":"Cardiac fibrosis induced by TGF-β1 upregulates CRLF1 expression through the SMAD-dependent (not SMAD-independent) signaling pathway; CRLF1 then promotes cardiac fibroblast viability, collagen production, proliferation, and myofibroblast transformation by activating the ERK1/2 signaling pathway.","method":"Gain- and loss-of-function in neonatal mouse cardiac fibroblasts; ERK1/2 inhibitor; SMAD-dependent and SMAD-independent TGF-β1 pathway inhibitors; Western blotting","journal":"Journal of Zhejiang University. Science. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with specific inhibitors, gain/loss-of-function; single lab","pmids":["37551555"],"is_preprint":false},{"year":2024,"finding":"CRLF1 is a novel component of the mTORC2 complex; it enhances AKT Ser473 phosphorylation by strengthening the interaction between AKT and SIN1, thereby inhibiting the ASK1-JNK-caspase-3-gasdermin E pyroptotic pathway and conferring chemoresistance in ovarian cancer. Binding-defective CRLF1 variants impair AKT-SIN1 interaction and promote pyroptosis.","method":"Co-immunoprecipitation (AKT-SIN1 interaction), mTORC2 complex biochemistry, AKT Ser473 phosphorylation assays, gain/loss-of-function with binding-defective mutants, pyroptosis assays, in vitro chemosensitivity assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for complex membership, mutagenesis to define binding interface, multiple functional readouts; single lab","pmids":["39256356"],"is_preprint":false},{"year":2024,"finding":"A homodimeric CRLF1 complex stimulates chondrogenic differentiation of BMSCs via Smad2/3 signaling, while a heterodimeric CRLF1/CLC (CLCF1) complex stimulates catabolic events in chondrocytes via STAT3 activation, demonstrating that the oligomeric state of CRLF1 determines its downstream signaling outcome.","method":"CRLF1 overexpression in BMSCs (homodimer secretion confirmed), chondrogenic differentiation assays (alcian blue staining, gene expression), immunoblot for Smad2/3 and STAT3 signaling, interleukin-1β-treated chondrocyte cell line, in vivo rabbit femoral osteochondral defect model","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — distinct complexes (homo- vs. heterodimer) tested separately with specific pathway readouts, in vivo validation; single lab","pmids":["38727293"],"is_preprint":false},{"year":2025,"finding":"The CRLF1/CLCF1 heterodimer activates JAK/STAT3 signaling in nucleus pulposus cells, enhancing production of senescence-associated secretory phenotype (SASP) factors and accelerating cell senescence; CRLF1 knockdown reduces extracellular matrix degradation and alleviates intervertebral disc degeneration in vivo.","method":"Fluorescence colocalization and co-immunoprecipitation (CRLF1-CLCF1 heterodimer); RNA-seq; in vitro NPC senescence assays; in vivo IVDD mouse model; pain-behavior tests","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — heterodimer confirmed by Co-IP and colocalization, JAK/STAT3 pathway activation shown, in vivo validation; single lab","pmids":["39986601"],"is_preprint":false},{"year":2017,"finding":"CRLF1 mutations causing familial achalasia result in severely impaired CRLF1 protein secretion from transfected cells, consistent with the secretion-defect mechanism identified in CS/CISS1, and extending the phenotypic spectrum of CRLF1-related disorders to isolated achalasia.","method":"Next-generation sequencing; co-immunoprecipitation/secretion assay in transfected cells for the novel c.178T>A (p.Cys60Ser) variant","journal":"Clinical genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — secretion assay in transfected cells for single variant, single lab, limited mechanistic detail in abstract","pmids":["27976805"],"is_preprint":false},{"year":2023,"finding":"The lncRNA MIR22HG suppresses chondrogenic differentiation of human adipose-derived stem cells by binding to CTCF, which then binds the CRLF1 promoter to upregulate CRLF1 expression; inhibition of CRLF1 reverses the anti-chondrogenic effect of MIR22HG.","method":"RNA pulldown / RIP for MIR22HG-CTCF interaction; ChIP for CTCF binding to CRLF1 promoter; gain/loss-of-function; chondrogenic differentiation markers","journal":"Functional & integrative genomics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — CTCF-CRLF1 promoter binding shown by ChIP, but abstract lacks detail on rigor of MIR22HG-CTCF binding assay; single lab","pmids":["37910254"],"is_preprint":false},{"year":2024,"finding":"ENO1 and CRLF1 physically interact (co-immunoprecipitation and co-immunofluorescence), and ENO1 silencing protects against IL-1β-induced chondrocyte inflammation, apoptosis, and matrix degradation; CRLF1 overexpression reverses ENO1 knockdown effects, placing ENO1 upstream of CRLF1 in OA chondrocyte pathology.","method":"Co-immunoprecipitation; immunofluorescence; siRNA knockdown and overexpression in IL-1β-stimulated C-28/I2 chondrocytes; NF-κB pathway assays","journal":"Tissue & cell","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP confirms potential interaction, functional epistasis shown but pathway mechanism not fully resolved; single lab","pmids":["39116531"],"is_preprint":false},{"year":2026,"finding":"CRLF1, predominantly secreted by activated cardiac fibroblasts, acts as a paracrine factor driving cardiomyocyte hypertrophy by activating the LIFR-JAK1/2-STAT3 signaling cascade; genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of downstream STAT3 signaling markedly attenuates hypertrophic cardiomyopathy phenotypes in mouse and human HCM models.","method":"Single-cell RNA sequencing (cellular source identification); bulk RNA-seq and WGCNA; gain- and loss-of-function studies; Myh6 R404Q/+ mouse model; in vitro human cardiomyocyte assays; pharmacological pathway inhibition","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (scRNA-seq, genetic KO in fibroblasts, pharmacological inhibition, cross-species validation), consistent results across human and mouse models","pmids":["41838796"],"is_preprint":false},{"year":2024,"finding":"CRLF1 promotes prostate cancer cell growth and invasion via upregulation of COMP (cartilage oligomeric matrix protein), which activates the FAK/PI3K/AKT signaling cascade; COMP knockdown abrogates the cancer-promoting effects of CRLF1 overexpression.","method":"Bioinformatics (protein interaction networks, TCGA); qRT-PCR and Western blot; Transwell invasion, CCK-8, wound healing assays; in vivo xenograft; genetic perturbation (OE and KD) of CRLF1 and COMP","journal":"Cancers","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional epistasis (COMP KD rescues CRLF1 OE), but direct CRLF1-COMP interaction not demonstrated biochemically; single lab","pmids":["42122189"],"is_preprint":false},{"year":2026,"finding":"ZBTB7A transcriptionally activates CRLF1 expression in ovarian cancer cells; CRLF1 knockdown abrogates ZBTB7A-induced cell proliferation and migration, defining a functional ZBTB7A/CRLF1 oncogenic axis.","method":"Transcriptomic analyses; RNA interference and overexpression functional assays; proliferation, clonogenic, migration assays","journal":"Oncology reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — epistasis established by rescue experiment, but direct transcriptional activation (e.g., ChIP for ZBTB7A at CRLF1 promoter) not explicitly stated in abstract; single lab","pmids":["41891980"],"is_preprint":false}],"current_model":"CRLF1 is a secreted soluble cytokine receptor that functions primarily as a heterodimer with CLCF1/CLC; this complex competes with CNTF for binding to the CNTFR complex (CNTFR/gp130/LIFRβ), activating JAK-STAT3 and Smad2/3 signaling in target cells, while sorLA mediates endocytosis and lysosomal downregulation of the CRLF1/CLC/CNTFRα trimeric complex. CRLF1 also acts as a novel component of mTORC2, enhancing AKT Ser473 phosphorylation via SIN1, and in multiple tissue contexts promotes fibrosis and hypertrophy through ERK1/2 activation downstream of TGF-β1/SMAD; loss-of-function mutations that impair CRLF1 secretion underlie Crisponi/cold-induced sweating syndrome by disrupting CNTFR pathway signaling in the autonomic nervous system."},"narrative":{"mechanistic_narrative":"CRLF1 is a secreted soluble cytokine receptor subunit that functions as a co-ligand in the CNTF receptor pathway, where it forms a heterodimer with CLCF1/CLC that competes with CNTF for binding to the CNTFR complex [PMID:17436251, PMID:17436252]. Loss-of-function mutations that impair CRLF1 secretion cause autosomal-recessive cold-induced sweating syndrome (CISS1)/Crisponi syndrome, with phenotypic severity tracking the degree of secretion defect, establishing a requirement for CRLF1 in autonomic nervous system development [PMID:12509788, PMID:21326283]. The oligomeric state of CRLF1 dictates its signaling output: a homodimeric complex drives Smad2/3 signaling to promote chondrogenic differentiation, whereas the CRLF1/CLCF1 heterodimer activates JAK/STAT3 to drive catabolic and senescence-associated programs [PMID:38727293, PMID:39986601]. Surface signaling is restrained by the endocytic receptor sorLA, which CRLF1 bridges to CNTFRα to drive CNTFRα internalization and lysosomal degradation [PMID:28117780]. In disease contexts CRLF1 is induced by TGF-β1 via SMAD3 and acts as a profibrotic, prohypertrophic effector through ERK1/2 activation in ligamentum flavum and cardiac fibroblasts [PMID:33072735, PMID:37551555], and as a fibroblast-derived paracrine factor it drives cardiomyocyte hypertrophy through LIFR-JAK1/2-STAT3 signaling [PMID:41838796]. CRLF1 also acts intracellularly as a component of mTORC2, strengthening the AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis [PMID:39256356], and promotes proliferation, migration, and EMT across several carcinomas via ERK1/2 and AKT signaling [PMID:29515111, PMID:32982961].","teleology":[{"year":2002,"claim":"Established CRLF1 as a disease gene by showing loss-of-function mutations cause an autosomal-recessive disorder, implicating it in autonomic and developmental physiology before its molecular role was understood.","evidence":"Genome-wide linkage mapping and DNA sequencing in affected CISS1 families","pmids":["12509788"],"confidence":"High","gaps":["Did not define the molecular pathway disrupted","No biochemical mechanism for how mutations cause disease"]},{"year":2007,"claim":"Placed CRLF1 in a defined signaling pathway by showing it heterodimerizes with CLCF1/CLC and competes with CNTF at the CNTFR complex, providing the molecular framework for its disease role.","evidence":"Biochemical characterization, mutation analysis, and patient fibroblast expression assays","pmids":["17436251","17436252"],"confidence":"High","gaps":["Did not resolve how secretion defects translate into receptor pathway failure in vivo","Downstream signaling effectors not detailed"]},{"year":2011,"claim":"Linked genotype to phenotype mechanistically by demonstrating that the kinetics of mutant CRLF1 secretion, rather than presence of mutation per se, determine clinical severity.","evidence":"Secretion assays of mutant CRLF1 in cells correlated with clinical data across 19 patients","pmids":["21326283"],"confidence":"Medium","gaps":["Single lab","Does not explain tissue-specific manifestations"]},{"year":2013,"claim":"Revealed a CNTFR-independent function by showing CRLF1 protects neuroblastoma cells against oxidative stress cell-autonomously, indicating roles beyond its canonical co-ligand activity.","evidence":"siRNA knockdown and overexpression with 6-OHDA toxicity assays in differentiated neuroblastoma cells","pmids":["23818941"],"confidence":"Medium","gaps":["Molecular mediator of protection not identified","Single cell type, single lab"]},{"year":2017,"claim":"Defined a downregulation mechanism by showing CRLF1 bridges CNTFRα to the endocytic receptor sorLA, driving receptor internalization and lysosomal degradation to dampen signaling.","evidence":"Western blotting, lysosomal inhibition, and immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1","pmids":["28117780"],"confidence":"Medium","gaps":["Physiological relevance in autonomic tissues not tested","Single lab"]},{"year":2020,"claim":"Established CRLF1 as a TGF-β1/SMAD3-induced profibrotic effector acting through ERK signaling, extending its biology to fibrosis and tissue hypertrophy.","evidence":"Tissue transcriptomics/proteomics, SMAD3 inhibitor studies, and in vivo/in vitro knockdown and overexpression in ligamentum flavum models","pmids":["33072735"],"confidence":"Medium","gaps":["Mechanism of post-transcriptional ERK enhancement not resolved","Single tissue context"]},{"year":2020,"claim":"Identified MYH9 as a direct binding partner stabilizing CRLF1 and traced an ERK-ETV4-MMP1 axis driving cancer metastasis, defining a concrete oncogenic mechanism.","evidence":"Reciprocal Co-IP, RNA-seq, ChIP, and in vitro/in vivo functional assays in papillary thyroid carcinoma","pmids":["32982961"],"confidence":"Medium","gaps":["Whether MYH9 interaction relates to secreted vs intracellular CRLF1 unclear","Single lab"]},{"year":2024,"claim":"Uncovered an intracellular function by identifying CRLF1 as an mTORC2 component that strengthens AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis-driven chemosensitivity.","evidence":"Co-IP, mTORC2 biochemistry, AKT phosphorylation assays, and binding-defective mutants in ovarian cancer cells","pmids":["39256356"],"confidence":"Medium","gaps":["Reconciliation with secreted CRLF1 biology not addressed","Structural basis of AKT-SIN1 bridging not defined"]},{"year":2024,"claim":"Showed that CRLF1 oligomeric state dictates signaling outcome, with homodimers driving Smad2/3 chondrogenesis and CRLF1/CLC heterodimers driving STAT3 catabolism.","evidence":"Distinct complex assays, pathway immunoblots, and in vivo rabbit osteochondral defect model","pmids":["38727293"],"confidence":"Medium","gaps":["What controls homo- vs heterodimer assembly in vivo unknown","Single lab"]},{"year":2025,"claim":"Connected the CRLF1/CLCF1 heterodimer to JAK/STAT3-driven cellular senescence and SASP production, implicating it in intervertebral disc degeneration.","evidence":"Co-IP and colocalization, RNA-seq, NPC senescence assays, and in vivo IVDD mouse model","pmids":["39986601"],"confidence":"Medium","gaps":["Receptor used in NPCs not fully resolved","Single lab"]},{"year":2026,"claim":"Defined CRLF1 as a fibroblast-derived paracrine driver of cardiomyocyte hypertrophy via LIFR-JAK1/2-STAT3, validated genetically and pharmacologically across species.","evidence":"scRNA-seq, fibroblast-specific Crlf1 ablation, pharmacological STAT3 inhibition, and Myh6 R404Q/+ mouse and human HCM models","pmids":["41838796"],"confidence":"High","gaps":["Whether CLCF1 partnership is required in this context not detailed","Upstream inducers in HCM not fully mapped"]},{"year":null,"claim":"How CRLF1's distinct activities — secreted co-ligand, sorLA-mediated downregulator, intracellular mTORC2 component, and dimer-state-dependent signaling switch — are coordinated within a single cell or tissue remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating secreted and intracellular roles","Mechanism partitioning CRLF1 between secretion and cytoplasmic mTORC2 unknown","Tissue-specific receptor partner choice not systematically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,12,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,4,11]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,13]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,12,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,13,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,5,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,12]}],"complexes":["CRLF1/CLCF1 heterodimer","mTORC2","CNTFR complex"],"partners":["CLCF1","CNTFR","SORLA","MYH9","SIN1","AKT","ENO1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75462","full_name":"Cytokine receptor-like factor 1","aliases":["Cytokine-like factor 1","CLF-1","ZcytoR5"],"length_aa":422,"mass_kda":46.3,"function":"In complex with CLCF1, forms a heterodimeric neurotropic cytokine that plays a crucial role during neuronal development (Probable). May also play a regulatory role in the immune system","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O75462/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CRLF1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CRLF1","total_profiled":1310},"omim":[{"mim_id":"610313","title":"CRISPONI/COLD-INDUCED SWEATING SYNDROME 2; CISS2","url":"https://www.omim.org/entry/610313"},{"mim_id":"607672","title":"CARDIOTROPHIN-LIKE CYTOKINE FACTOR 1; CLCF1","url":"https://www.omim.org/entry/607672"},{"mim_id":"604237","title":"CYTOKINE RECEPTOR-LIKE FACTOR 1; CRLF1","url":"https://www.omim.org/entry/604237"},{"mim_id":"272430","title":"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1; CISS1","url":"https://www.omim.org/entry/272430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":231.1}],"url":"https://www.proteinatlas.org/search/CRLF1"},"hgnc":{"alias_symbol":["CLF-1","CLF","CISS","CISS1"],"prev_symbol":[]},"alphafold":{"accession":"O75462","domains":[{"cath_id":"2.60.40.10","chopping":"41-133","consensus_level":"high","plddt":92.4871,"start":41,"end":133},{"cath_id":"2.60.40.10","chopping":"140-234","consensus_level":"high","plddt":92.1506,"start":140,"end":234},{"cath_id":"2.60.40.10","chopping":"237-339","consensus_level":"high","plddt":91.2881,"start":237,"end":339}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75462","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75462-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75462-F1-predicted_aligned_error_v6.png","plddt_mean":80.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CRLF1","jax_strain_url":"https://www.jax.org/strain/search?query=CRLF1"},"sequence":{"accession":"O75462","fasta_url":"https://rest.uniprot.org/uniprotkb/O75462.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75462/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75462"}},"corpus_meta":[{"pmid":"17436252","id":"PMC_17436252","title":"Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17436252","citation_count":75,"is_preprint":false},{"pmid":"17436251","id":"PMC_17436251","title":"Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17436251","citation_count":55,"is_preprint":false},{"pmid":"29515111","id":"PMC_29515111","title":"CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29515111","citation_count":45,"is_preprint":false},{"pmid":"35055176","id":"PMC_35055176","title":"CRLF1 and CLCF1 in Development, Health and Disease.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35055176","citation_count":44,"is_preprint":false},{"pmid":"12509788","id":"PMC_12509788","title":"Cold-induced sweating syndrome is caused by mutations in the CRLF1 gene.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12509788","citation_count":44,"is_preprint":false},{"pmid":"21326283","id":"PMC_21326283","title":"Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21326283","citation_count":38,"is_preprint":false},{"pmid":"33072735","id":"PMC_33072735","title":"CRLF1 Is a Key Regulator in the Ligamentum Flavum Hypertrophy.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33072735","citation_count":36,"is_preprint":false},{"pmid":"21544417","id":"PMC_21544417","title":"Is chromosome in situ suppression (CISS) hybridization suited as a predictive test for intrinsic radiosensitivity in cancer patients?","date":"1996","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21544417","citation_count":32,"is_preprint":false},{"pmid":"27392078","id":"PMC_27392078","title":"Bi-allelic Mutations in KLHL7 Cause a Crisponi/CISS1-like Phenotype Associated with Early-Onset Retinitis Pigmentosa.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27392078","citation_count":30,"is_preprint":false},{"pmid":"32982961","id":"PMC_32982961","title":"CRLF1-MYH9 Interaction Regulates Proliferation and Metastasis of Papillary Thyroid Carcinoma Through the ERK/ETV4 Axis.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32982961","citation_count":29,"is_preprint":false},{"pmid":"20400119","id":"PMC_20400119","title":"Cold-induced sweating syndrome: CISS1 and CISS2: manifestations from infancy to adulthood. Four new cases.","date":"2010","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20400119","citation_count":26,"is_preprint":false},{"pmid":"34656128","id":"PMC_34656128","title":"miR-3065-3p promotes stemness and metastasis by targeting CRLF1 in colorectal cancer.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34656128","citation_count":25,"is_preprint":false},{"pmid":"24488861","id":"PMC_24488861","title":"Expanding the mutational spectrum of CRLF1 in Crisponi/CISS1 syndrome.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24488861","citation_count":20,"is_preprint":false},{"pmid":"23818941","id":"PMC_23818941","title":"Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23818941","citation_count":18,"is_preprint":false},{"pmid":"29561382","id":"PMC_29561382","title":"Preserved Cochlear CISS Signal is a Predictor for Hearing Preservation in Patients Treated for Vestibular Schwannoma With Stereotactic Radiosurgery.","date":"2018","source":"Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","url":"https://pubmed.ncbi.nlm.nih.gov/29561382","citation_count":17,"is_preprint":false},{"pmid":"39256356","id":"PMC_39256356","title":"CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39256356","citation_count":15,"is_preprint":false},{"pmid":"20186812","id":"PMC_20186812","title":"Cold-induced sweating syndrome with neonatal features of Crisponi syndrome: longitudinal observation of a patient homozygous for a CRLF1 mutation.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20186812","citation_count":15,"is_preprint":false},{"pmid":"34551709","id":"PMC_34551709","title":"Suppression of CRLF1 promotes the chondrogenic differentiation of bone marrow-derived mesenchymal stem and protects cartilage tissue from damage in osteoarthritis via activation of miR-320.","date":"2021","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34551709","citation_count":14,"is_preprint":false},{"pmid":"7889646","id":"PMC_7889646","title":"Familial translocation (X;3) (p22.3;p23): chromosomal in situ suppression (CISS) hybridization and inactivation pattern study.","date":"1994","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7889646","citation_count":12,"is_preprint":false},{"pmid":"1652549","id":"PMC_1652549","title":"Detection of APC region-specific signals by nonisotopic chromosomal in situ suppression (CISS)-hybridization using a microdissection library as a probe.","date":"1991","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1652549","citation_count":12,"is_preprint":false},{"pmid":"37551555","id":"PMC_37551555","title":"Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway.","date":"2023","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/37551555","citation_count":10,"is_preprint":false},{"pmid":"39986601","id":"PMC_39986601","title":"CRLF1/CLCF1 heterodimer involvement in intervertebral disc degeneration via exacerbation of extracellular matrix degradation and nucleus pulposus cell senescence.","date":"2025","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/39986601","citation_count":9,"is_preprint":false},{"pmid":"39137621","id":"PMC_39137621","title":"Tobacco smoking is associated with sex- and plaque-type specific upregulation of CRLF1 in atherosclerotic lesions.","date":"2024","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/39137621","citation_count":9,"is_preprint":false},{"pmid":"23026229","id":"PMC_23026229","title":"Multiple small hyperintense lesions in the subcortical white matter on cranial MR images in two Turkish brothers with cold-induced sweating syndrome caused by a novel missense mutation in the CRLF1 gene.","date":"2012","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/23026229","citation_count":9,"is_preprint":false},{"pmid":"23181498","id":"PMC_23181498","title":"Novel CRLF1 gene mutation in a newborn infant diagnosed with Crisponi syndrome.","date":"2012","source":"Congenital anomalies","url":"https://pubmed.ncbi.nlm.nih.gov/23181498","citation_count":9,"is_preprint":false},{"pmid":"30142437","id":"PMC_30142437","title":"Bi-allelic c.181_183delTGT in BTB domain of KLHL7 is associated with overlapping phenotypes of Crisponi/CISS1-like and Bohring-Opitz like syndrome.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30142437","citation_count":9,"is_preprint":false},{"pmid":"24032286","id":"PMC_24032286","title":"Crisponi syndrome: a new mutation in CRLF1 gene associated with moderate outcome.","date":"2013","source":"Genetic counseling (Geneva, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/24032286","citation_count":8,"is_preprint":false},{"pmid":"33166464","id":"PMC_33166464","title":"Identification and Reactivity of s-cis,s-cis-Dihydroxycarbene, a New [CH2O2] Intermediate.","date":"2020","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/33166464","citation_count":8,"is_preprint":false},{"pmid":"36749750","id":"PMC_36749750","title":"Light-Amplified CISS-Based Hybrid QD-DNA Impedimetric Device for DNA Hybridization Detection.","date":"2023","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36749750","citation_count":7,"is_preprint":false},{"pmid":"27976805","id":"PMC_27976805","title":"Mutations in CRLF1 cause familial achalasia.","date":"2017","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27976805","citation_count":7,"is_preprint":false},{"pmid":"37439472","id":"PMC_37439472","title":"Spin-dependent electrified protein interfaces for probing the CISS effect.","date":"2023","source":"The Journal of chemical physics","url":"https://pubmed.ncbi.nlm.nih.gov/37439472","citation_count":7,"is_preprint":false},{"pmid":"21691203","id":"PMC_21691203","title":"Homozygous mutation of CRLF-1 gene in a Turkish newborn with Crisponi syndrome.","date":"2011","source":"Clinical dysmorphology","url":"https://pubmed.ncbi.nlm.nih.gov/21691203","citation_count":7,"is_preprint":false},{"pmid":"39116531","id":"PMC_39116531","title":"ENO1 regulates IL-1β-induced chondrocyte inflammation, apoptosis and matrix degradation possibly through the potential binding to CRLF1.","date":"2024","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/39116531","citation_count":6,"is_preprint":false},{"pmid":"24008591","id":"PMC_24008591","title":"Cold-induced sweating syndrome type 1, with a CRLF1 level mutation, previously associated with Crisponi syndrome.","date":"2013","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/24008591","citation_count":6,"is_preprint":false},{"pmid":"8370154","id":"PMC_8370154","title":"A retrospective CISS hybridization analysis of a case with de novo translocation t(18;22) resulting in an 18p- syndrome.","date":"1993","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8370154","citation_count":6,"is_preprint":false},{"pmid":"37910254","id":"PMC_37910254","title":"Long non-coding RNA MIR22HG suppresses the chondrogenic differentiation of human adipose-derived stem cells by interacting with CTCF to upregulate CRLF1.","date":"2023","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37910254","citation_count":5,"is_preprint":false},{"pmid":"36312421","id":"PMC_36312421","title":"CISS-Based Label-Free Novel Electrochemical Impedimetric Detection of UVC-Induced DNA Damage.","date":"2022","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/36312421","citation_count":5,"is_preprint":false},{"pmid":"7118436","id":"PMC_7118436","title":"The rate of s-cis/s-trans isomerization in angiotensin II is at least 70-fold greater than in His-Pro and is not rate limiting in receptor binding.","date":"1982","source":"International journal of peptide and protein research","url":"https://pubmed.ncbi.nlm.nih.gov/7118436","citation_count":5,"is_preprint":false},{"pmid":"38727293","id":"PMC_38727293","title":"Cytokine Receptor-like Factor 1 (CRLF1) and Its Role in Osteochondral Repair.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38727293","citation_count":4,"is_preprint":false},{"pmid":"26804344","id":"PMC_26804344","title":"Crisponi/CISS1 syndrome: A case series.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/26804344","citation_count":4,"is_preprint":false},{"pmid":"24613578","id":"PMC_24613578","title":"A new Turkish infant with clinical features of CS/CISS1 syndrome and homozygous CRLF1 mutation.","date":"2014","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24613578","citation_count":4,"is_preprint":false},{"pmid":"1797087","id":"PMC_1797087","title":"Characterization of marker chromosomes in Namalva cells by chromosomal in situ suppression (CISS) hybridization and R-banding.","date":"1991","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1797087","citation_count":4,"is_preprint":false},{"pmid":"38262564","id":"PMC_38262564","title":"Identification and validation of CRLF1 and NRG1 as immune-related signatures in hypertrophic scar.","date":"2024","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38262564","citation_count":3,"is_preprint":false},{"pmid":"35984556","id":"PMC_35984556","title":"Novel Mutations in CRLF1: Case Reports with Crisponi Syndrome.","date":"2022","source":"Indian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/35984556","citation_count":3,"is_preprint":false},{"pmid":"27054527","id":"PMC_27054527","title":"Corneal alterations in Crisponi/CISS1 syndrome: A slit-lamp biomicroscopy and in vivo confocal microscopy corneal report.","date":"2016","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27054527","citation_count":3,"is_preprint":false},{"pmid":"39580860","id":"PMC_39580860","title":"Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39580860","citation_count":2,"is_preprint":false},{"pmid":"35699517","id":"PMC_35699517","title":"Clinical and molecular genetic findings of Crisponi/cold-induced sweating syndrome (CS/CISS) spectrum in patients from Turkey.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35699517","citation_count":2,"is_preprint":false},{"pmid":"33910095","id":"PMC_33910095","title":"Three new cases of Crisponi /cold induced sweating syndrome (CS/CISS1) in Turkish families.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33910095","citation_count":2,"is_preprint":false},{"pmid":"30613855","id":"PMC_30613855","title":"Interdural high signal on CISS sequence: an alternative CSF pathway?","date":"2019","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/30613855","citation_count":2,"is_preprint":false},{"pmid":"39128688","id":"PMC_39128688","title":"The role of cytokine receptor-like factor 1 (CRLF1) in facet joint osteoarthritis pathogenesis.","date":"2024","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/39128688","citation_count":1,"is_preprint":false},{"pmid":"28117780","id":"PMC_28117780","title":"SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry.","date":"2017","source":"Journal of visualized experiments : JoVE","url":"https://pubmed.ncbi.nlm.nih.gov/28117780","citation_count":1,"is_preprint":false},{"pmid":"41838796","id":"PMC_41838796","title":"CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.","date":"2026","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/41838796","citation_count":0,"is_preprint":false},{"pmid":"40772948","id":"PMC_40772948","title":"Cavity-mediated enhancement of CISS in DNA junctions.","date":"2025","source":"Physical chemistry chemical physics : PCCP","url":"https://pubmed.ncbi.nlm.nih.gov/40772948","citation_count":0,"is_preprint":false},{"pmid":"42122189","id":"PMC_42122189","title":"CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway.","date":"2026","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/42122189","citation_count":0,"is_preprint":false},{"pmid":"41891980","id":"PMC_41891980","title":"ZBTB7A promotes malignant phenotypes in ovarian cancer through transcriptional activation of CRLF1.","date":"2026","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41891980","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.06.686954","title":"A phage-derived reconfigurable effector associated with an actinobacterial contractile nanomachine tailors bacterial responses to competition","date":"2025-11-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.06.686954","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.08.681156","title":"Stepwise firing mechanism of an extracellular contractile injection system","date":"2025-10-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.08.681156","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.14.25331467","title":"Mesoscale CISS Imaging for the Detection of Dural Defects in Spinal CSF Leaks","date":"2025-07-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.14.25331467","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.11.669294","title":"Thermophilic bacteria employ a contractile injection system in hot spring microbial mats","date":"2025-08-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.11.669294","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.20.649488","title":"Structural characterization of an extracellular contractile injection system from Photorhabdus luminescens in extended and contracted states.","date":"2025-04-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.20.649488","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.28.672839","title":"The spike tip protein of bacteriophage T4","date":"2025-08-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.28.672839","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.06.25329105","title":"Magnetic resonance imaging and the evaluation of vestibular schwannomas: a systematic review","date":"2025-06-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.06.25329105","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.01.657177","title":"Structure of a novel contractile injection system in  <i>Salmonella enterica</i>  subsp.  <i>salamae</i>","date":"2025-06-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.01.657177","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.24.25326365","title":"Beyond Medical Prescription: Unveiling Coping Strategies’ Role Between Perceived Quality of Care and Treatment Adherence among Hypertensive Patients","date":"2025-04-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.24.25326365","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.06.606146","title":"Defining the cardiac fibroblast secretome in the healthy and infarcted mouse heart","date":"2024-08-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.06.606146","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32222,"output_tokens":5353,"usd":0.088481,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13679,"output_tokens":3726,"usd":0.080772,"stage2_stop_reason":"end_turn"},"total_usd":0.169253,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"CRLF1 forms a heterodimer complex with cardiotrophin-like cytokine factor 1 (CLCF1/CLC), and this heterodimer competes with ciliary neurotrophic factor (CNTF) for binding to the CNTF receptor (CNTFR) complex, placing CRLF1 in the CNTFR signaling pathway.\",\n      \"method\": \"Biochemical characterization; mutation analysis; mRNA expression in patient fibroblasts by real-time quantitative PCR\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — established by two independent groups in the same journal issue (PMID 17436251, 17436252), supported by prior literature on the heterodimer complex and consistent functional framing\",\n      \"pmids\": [\"17436251\", \"17436252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Loss-of-function mutations in CRLF1 cause cold-induced sweating syndrome (CISS1), an autosomal recessive disorder, indicating that CRLF1 is required for normal developmental and autonomic nervous system function.\",\n      \"method\": \"Genome-wide linkage mapping, candidate region fine-mapping, DNA sequencing in affected families\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic mapping and sequencing in multiple families, independently replicated in subsequent studies\",\n      \"pmids\": [\"12509788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Phenotypic severity of CRLF1-associated disorders (Crisponi syndrome vs. CISS1) mainly depends on altered kinetics of secretion of the mutated CRLF1 protein; mutations that more severely impair CRLF1 secretion correlate with more severe clinical outcome.\",\n      \"method\": \"Functional secretion assays of mutant CRLF1 proteins from patient-derived or transfected cells; clinical analysis of 19 patients\",\n      \"journal\": \"European journal of human genetics : EJHG\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — secretion kinetics assayed in cells for multiple mutations, correlated with clinical data in a large patient cohort; single lab\",\n      \"pmids\": [\"21326283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CRLF1 protects differentiated neuroblastoma cells against 6-hydroxydopamine-induced oxidative stress by a cell-autonomous mechanism that is independent of its known role as a co-ligand for the CNTF receptor (gp130/JAK signaling pathway).\",\n      \"method\": \"Loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in neuroblastoma cells; 6-OHDA toxicity assay; differentiation state comparison\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both necessary and sufficient evidence by KD and OE, receptor-independence tested directly; single lab\",\n      \"pmids\": [\"23818941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CLF-1 (CRLF1) contains a binding site for the endocytic receptor sorLA; sorLA-expressing cells rapidly internalize CLF-1 and CLC:CLF-1, and in cells co-expressing CNTFRα and sorLA, CLF-1 bridges CNTFRα to sorLA, driving CNTFRα internalization and lysosomal degradation, thereby downregulating surface CNTFRα and reducing CLC:CLF-1 signaling.\",\n      \"method\": \"Western blotting, lysosomal enzyme inhibition, immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1\",\n      \"journal\": \"Journal of visualized experiments : JoVE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Western blot, inhibitor studies, immunocytochemistry), single lab\",\n      \"pmids\": [\"28117780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRLF1 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition in papillary thyroid carcinoma cells by activating the ERK1/2 and AKT signaling pathways; these oncogenic effects are suppressed by MEK inhibitor U0126 or AKT inhibitor MK-2206.\",\n      \"method\": \"Loss-of-function and gain-of-function assays in PTC cell lines; in vitro migration/invasion; in vivo tumor growth; Western blotting of ERK1/2 and AKT phosphorylation; pharmacological inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays (in vitro and in vivo), pathway validated by specific inhibitors; single lab\",\n      \"pmids\": [\"29515111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRLF1 directly binds MYH9, which enhances CRLF1 protein stability; this interaction promotes PTC cell proliferation and metastasis via ERK pathway activation and upregulation of transcription factor ETV4, which in turn binds the MMP1 promoter to induce MMP1 expression.\",\n      \"method\": \"Co-immunoprecipitation (direct binding), RNA-sequencing (ETV4 as downstream target), ChIP assay (ETV4 binding MMP1 promoter), in vitro and in vivo functional assays, Western blotting\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, RNA-seq, in vivo validation; single lab\",\n      \"pmids\": [\"32982961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TGF-β1 upregulates CRLF1 mRNA expression in ligamentum flavum cells via the SMAD3 pathway; CRLF1 in turn enhances fibrosis via ERK signaling at the post-transcriptional level, and CRLF1 knockdown reduces fibrosis caused by inflammatory cytokines and mechanical stress. In vivo, CRLF1 overexpression causes ligamentum flavum hypertrophy.\",\n      \"method\": \"Transcriptome and proteomics of human LF tissue; immunohistochemistry; SMAD3 pathway inhibitor studies; CRLF1 knockdown and overexpression in vivo (bipedal-standing mouse model) and in vitro\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including in vivo mouse model and in vitro mechanistic dissection; single lab\",\n      \"pmids\": [\"33072735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-3065-3p directly targets and suppresses CRLF1 mRNA (validated by luciferase reporter assay), and CRLF1 acts downstream of miR-3065-3p to inhibit stemness in colorectal cancer; CRLF1 knockdown promotes, and its overexpression restores, the pro-stemness effects regulated by this miRNA.\",\n      \"method\": \"Luciferase reporter assay for direct miR-3065-3p/CRLF1 interaction; gain/loss-of-function in colorectal cancer cell lines and orthotopic xenograft; stemness markers (NANOG, OCT4, SOX2, ALDH activity, sphere formation)\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction validated by luciferase assay, functional rescue experiments, in vivo model; single lab\",\n      \"pmids\": [\"34656128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRLF1 is a direct target of miR-320 in bone marrow-derived mesenchymal stem cells (BMSCs); suppression of CRLF1 promotes chondrogenic differentiation of BMSCs and protects cartilage from OA damage; miR-320 overexpression reverses CRLF1-driven inhibition of chondrogenesis and promotion of apoptosis.\",\n      \"method\": \"Luciferase reporter assay; miR-320 overexpression; CRLF1 knockdown; chondrogenic differentiation assays in BMSCs; DMM mouse OA model\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting validated, functional rescue in vitro and in vivo OA model; single lab\",\n      \"pmids\": [\"34551709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cardiac fibrosis induced by TGF-β1 upregulates CRLF1 expression through the SMAD-dependent (not SMAD-independent) signaling pathway; CRLF1 then promotes cardiac fibroblast viability, collagen production, proliferation, and myofibroblast transformation by activating the ERK1/2 signaling pathway.\",\n      \"method\": \"Gain- and loss-of-function in neonatal mouse cardiac fibroblasts; ERK1/2 inhibitor; SMAD-dependent and SMAD-independent TGF-β1 pathway inhibitors; Western blotting\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with specific inhibitors, gain/loss-of-function; single lab\",\n      \"pmids\": [\"37551555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRLF1 is a novel component of the mTORC2 complex; it enhances AKT Ser473 phosphorylation by strengthening the interaction between AKT and SIN1, thereby inhibiting the ASK1-JNK-caspase-3-gasdermin E pyroptotic pathway and conferring chemoresistance in ovarian cancer. Binding-defective CRLF1 variants impair AKT-SIN1 interaction and promote pyroptosis.\",\n      \"method\": \"Co-immunoprecipitation (AKT-SIN1 interaction), mTORC2 complex biochemistry, AKT Ser473 phosphorylation assays, gain/loss-of-function with binding-defective mutants, pyroptosis assays, in vitro chemosensitivity assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for complex membership, mutagenesis to define binding interface, multiple functional readouts; single lab\",\n      \"pmids\": [\"39256356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A homodimeric CRLF1 complex stimulates chondrogenic differentiation of BMSCs via Smad2/3 signaling, while a heterodimeric CRLF1/CLC (CLCF1) complex stimulates catabolic events in chondrocytes via STAT3 activation, demonstrating that the oligomeric state of CRLF1 determines its downstream signaling outcome.\",\n      \"method\": \"CRLF1 overexpression in BMSCs (homodimer secretion confirmed), chondrogenic differentiation assays (alcian blue staining, gene expression), immunoblot for Smad2/3 and STAT3 signaling, interleukin-1β-treated chondrocyte cell line, in vivo rabbit femoral osteochondral defect model\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — distinct complexes (homo- vs. heterodimer) tested separately with specific pathway readouts, in vivo validation; single lab\",\n      \"pmids\": [\"38727293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The CRLF1/CLCF1 heterodimer activates JAK/STAT3 signaling in nucleus pulposus cells, enhancing production of senescence-associated secretory phenotype (SASP) factors and accelerating cell senescence; CRLF1 knockdown reduces extracellular matrix degradation and alleviates intervertebral disc degeneration in vivo.\",\n      \"method\": \"Fluorescence colocalization and co-immunoprecipitation (CRLF1-CLCF1 heterodimer); RNA-seq; in vitro NPC senescence assays; in vivo IVDD mouse model; pain-behavior tests\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — heterodimer confirmed by Co-IP and colocalization, JAK/STAT3 pathway activation shown, in vivo validation; single lab\",\n      \"pmids\": [\"39986601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CRLF1 mutations causing familial achalasia result in severely impaired CRLF1 protein secretion from transfected cells, consistent with the secretion-defect mechanism identified in CS/CISS1, and extending the phenotypic spectrum of CRLF1-related disorders to isolated achalasia.\",\n      \"method\": \"Next-generation sequencing; co-immunoprecipitation/secretion assay in transfected cells for the novel c.178T>A (p.Cys60Ser) variant\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — secretion assay in transfected cells for single variant, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"27976805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The lncRNA MIR22HG suppresses chondrogenic differentiation of human adipose-derived stem cells by binding to CTCF, which then binds the CRLF1 promoter to upregulate CRLF1 expression; inhibition of CRLF1 reverses the anti-chondrogenic effect of MIR22HG.\",\n      \"method\": \"RNA pulldown / RIP for MIR22HG-CTCF interaction; ChIP for CTCF binding to CRLF1 promoter; gain/loss-of-function; chondrogenic differentiation markers\",\n      \"journal\": \"Functional & integrative genomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — CTCF-CRLF1 promoter binding shown by ChIP, but abstract lacks detail on rigor of MIR22HG-CTCF binding assay; single lab\",\n      \"pmids\": [\"37910254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ENO1 and CRLF1 physically interact (co-immunoprecipitation and co-immunofluorescence), and ENO1 silencing protects against IL-1β-induced chondrocyte inflammation, apoptosis, and matrix degradation; CRLF1 overexpression reverses ENO1 knockdown effects, placing ENO1 upstream of CRLF1 in OA chondrocyte pathology.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence; siRNA knockdown and overexpression in IL-1β-stimulated C-28/I2 chondrocytes; NF-κB pathway assays\",\n      \"journal\": \"Tissue & cell\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP confirms potential interaction, functional epistasis shown but pathway mechanism not fully resolved; single lab\",\n      \"pmids\": [\"39116531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CRLF1, predominantly secreted by activated cardiac fibroblasts, acts as a paracrine factor driving cardiomyocyte hypertrophy by activating the LIFR-JAK1/2-STAT3 signaling cascade; genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of downstream STAT3 signaling markedly attenuates hypertrophic cardiomyopathy phenotypes in mouse and human HCM models.\",\n      \"method\": \"Single-cell RNA sequencing (cellular source identification); bulk RNA-seq and WGCNA; gain- and loss-of-function studies; Myh6 R404Q/+ mouse model; in vitro human cardiomyocyte assays; pharmacological pathway inhibition\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (scRNA-seq, genetic KO in fibroblasts, pharmacological inhibition, cross-species validation), consistent results across human and mouse models\",\n      \"pmids\": [\"41838796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRLF1 promotes prostate cancer cell growth and invasion via upregulation of COMP (cartilage oligomeric matrix protein), which activates the FAK/PI3K/AKT signaling cascade; COMP knockdown abrogates the cancer-promoting effects of CRLF1 overexpression.\",\n      \"method\": \"Bioinformatics (protein interaction networks, TCGA); qRT-PCR and Western blot; Transwell invasion, CCK-8, wound healing assays; in vivo xenograft; genetic perturbation (OE and KD) of CRLF1 and COMP\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional epistasis (COMP KD rescues CRLF1 OE), but direct CRLF1-COMP interaction not demonstrated biochemically; single lab\",\n      \"pmids\": [\"42122189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZBTB7A transcriptionally activates CRLF1 expression in ovarian cancer cells; CRLF1 knockdown abrogates ZBTB7A-induced cell proliferation and migration, defining a functional ZBTB7A/CRLF1 oncogenic axis.\",\n      \"method\": \"Transcriptomic analyses; RNA interference and overexpression functional assays; proliferation, clonogenic, migration assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — epistasis established by rescue experiment, but direct transcriptional activation (e.g., ChIP for ZBTB7A at CRLF1 promoter) not explicitly stated in abstract; single lab\",\n      \"pmids\": [\"41891980\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CRLF1 is a secreted soluble cytokine receptor that functions primarily as a heterodimer with CLCF1/CLC; this complex competes with CNTF for binding to the CNTFR complex (CNTFR/gp130/LIFRβ), activating JAK-STAT3 and Smad2/3 signaling in target cells, while sorLA mediates endocytosis and lysosomal downregulation of the CRLF1/CLC/CNTFRα trimeric complex. CRLF1 also acts as a novel component of mTORC2, enhancing AKT Ser473 phosphorylation via SIN1, and in multiple tissue contexts promotes fibrosis and hypertrophy through ERK1/2 activation downstream of TGF-β1/SMAD; loss-of-function mutations that impair CRLF1 secretion underlie Crisponi/cold-induced sweating syndrome by disrupting CNTFR pathway signaling in the autonomic nervous system.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CRLF1 is a secreted soluble cytokine receptor subunit that functions as a co-ligand in the CNTF receptor pathway, where it forms a heterodimer with CLCF1/CLC that competes with CNTF for binding to the CNTFR complex [#0]. Loss-of-function mutations that impair CRLF1 secretion cause autosomal-recessive cold-induced sweating syndrome (CISS1)/Crisponi syndrome, with phenotypic severity tracking the degree of secretion defect, establishing a requirement for CRLF1 in autonomic nervous system development [#1, #2]. The oligomeric state of CRLF1 dictates its signaling output: a homodimeric complex drives Smad2/3 signaling to promote chondrogenic differentiation, whereas the CRLF1/CLCF1 heterodimer activates JAK/STAT3 to drive catabolic and senescence-associated programs [#12, #13]. Surface signaling is restrained by the endocytic receptor sorLA, which CRLF1 bridges to CNTFRα to drive CNTFRα internalization and lysosomal degradation [#4]. In disease contexts CRLF1 is induced by TGF-β1 via SMAD3 and acts as a profibrotic, prohypertrophic effector through ERK1/2 activation in ligamentum flavum and cardiac fibroblasts [#7, #10], and as a fibroblast-derived paracrine factor it drives cardiomyocyte hypertrophy through LIFR-JAK1/2-STAT3 signaling [#17]. CRLF1 also acts intracellularly as a component of mTORC2, strengthening the AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis [#11], and promotes proliferation, migration, and EMT across several carcinomas via ERK1/2 and AKT signaling [#5, #6].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established CRLF1 as a disease gene by showing loss-of-function mutations cause an autosomal-recessive disorder, implicating it in autonomic and developmental physiology before its molecular role was understood.\",\n      \"evidence\": \"Genome-wide linkage mapping and DNA sequencing in affected CISS1 families\",\n      \"pmids\": [\"12509788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular pathway disrupted\", \"No biochemical mechanism for how mutations cause disease\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed CRLF1 in a defined signaling pathway by showing it heterodimerizes with CLCF1/CLC and competes with CNTF at the CNTFR complex, providing the molecular framework for its disease role.\",\n      \"evidence\": \"Biochemical characterization, mutation analysis, and patient fibroblast expression assays\",\n      \"pmids\": [\"17436251\", \"17436252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how secretion defects translate into receptor pathway failure in vivo\", \"Downstream signaling effectors not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked genotype to phenotype mechanistically by demonstrating that the kinetics of mutant CRLF1 secretion, rather than presence of mutation per se, determine clinical severity.\",\n      \"evidence\": \"Secretion assays of mutant CRLF1 in cells correlated with clinical data across 19 patients\",\n      \"pmids\": [\"21326283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Does not explain tissue-specific manifestations\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a CNTFR-independent function by showing CRLF1 protects neuroblastoma cells against oxidative stress cell-autonomously, indicating roles beyond its canonical co-ligand activity.\",\n      \"evidence\": \"siRNA knockdown and overexpression with 6-OHDA toxicity assays in differentiated neuroblastoma cells\",\n      \"pmids\": [\"23818941\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediator of protection not identified\", \"Single cell type, single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a downregulation mechanism by showing CRLF1 bridges CNTFRα to the endocytic receptor sorLA, driving receptor internalization and lysosomal degradation to dampen signaling.\",\n      \"evidence\": \"Western blotting, lysosomal inhibition, and immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1\",\n      \"pmids\": [\"28117780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance in autonomic tissues not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established CRLF1 as a TGF-β1/SMAD3-induced profibrotic effector acting through ERK signaling, extending its biology to fibrosis and tissue hypertrophy.\",\n      \"evidence\": \"Tissue transcriptomics/proteomics, SMAD3 inhibitor studies, and in vivo/in vitro knockdown and overexpression in ligamentum flavum models\",\n      \"pmids\": [\"33072735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of post-transcriptional ERK enhancement not resolved\", \"Single tissue context\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified MYH9 as a direct binding partner stabilizing CRLF1 and traced an ERK-ETV4-MMP1 axis driving cancer metastasis, defining a concrete oncogenic mechanism.\",\n      \"evidence\": \"Reciprocal Co-IP, RNA-seq, ChIP, and in vitro/in vivo functional assays in papillary thyroid carcinoma\",\n      \"pmids\": [\"32982961\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MYH9 interaction relates to secreted vs intracellular CRLF1 unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovered an intracellular function by identifying CRLF1 as an mTORC2 component that strengthens AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis-driven chemosensitivity.\",\n      \"evidence\": \"Co-IP, mTORC2 biochemistry, AKT phosphorylation assays, and binding-defective mutants in ovarian cancer cells\",\n      \"pmids\": [\"39256356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with secreted CRLF1 biology not addressed\", \"Structural basis of AKT-SIN1 bridging not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed that CRLF1 oligomeric state dictates signaling outcome, with homodimers driving Smad2/3 chondrogenesis and CRLF1/CLC heterodimers driving STAT3 catabolism.\",\n      \"evidence\": \"Distinct complex assays, pathway immunoblots, and in vivo rabbit osteochondral defect model\",\n      \"pmids\": [\"38727293\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"What controls homo- vs heterodimer assembly in vivo unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected the CRLF1/CLCF1 heterodimer to JAK/STAT3-driven cellular senescence and SASP production, implicating it in intervertebral disc degeneration.\",\n      \"evidence\": \"Co-IP and colocalization, RNA-seq, NPC senescence assays, and in vivo IVDD mouse model\",\n      \"pmids\": [\"39986601\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor used in NPCs not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined CRLF1 as a fibroblast-derived paracrine driver of cardiomyocyte hypertrophy via LIFR-JAK1/2-STAT3, validated genetically and pharmacologically across species.\",\n      \"evidence\": \"scRNA-seq, fibroblast-specific Crlf1 ablation, pharmacological STAT3 inhibition, and Myh6 R404Q/+ mouse and human HCM models\",\n      \"pmids\": [\"41838796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CLCF1 partnership is required in this context not detailed\", \"Upstream inducers in HCM not fully mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CRLF1's distinct activities — secreted co-ligand, sorLA-mediated downregulator, intracellular mTORC2 component, and dimer-state-dependent signaling switch — are coordinated within a single cell or tissue remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating secreted and intracellular roles\", \"Mechanism partitioning CRLF1 between secretion and cytoplasmic mTORC2 unknown\", \"Tissue-specific receptor partner choice not systematically mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 12, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 4, 11]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 12, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 13, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 5, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 12]}\n    ],\n    \"complexes\": [\"CRLF1/CLCF1 heterodimer\", \"mTORC2\", \"CNTFR complex\"],\n    \"partners\": [\"CLCF1\", \"CNTFR\", \"sorLA\", \"MYH9\", \"SIN1\", \"AKT\", \"ENO1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}